ClinicalTrials.gg
TerminatedNCT01708161Updated Sep 13, 2018Results posted

A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors

A Phase 1/2 interventional study of BYL719 and AMG 479 in PIK3CA Mutated Advanced Solid Tumors and PIK3CA Amplified Advanced Solid Tumors, sponsored by Novartis Pharmaceuticals. Terminated at 10 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-09-13.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
47
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 38 studies testing alpelisib in Breast Neoplasms — 3 open to participants now, 12 under way, 2 of them phase 3. Alpelisib · Breast Neoplasms.

Enrollment
16th of 38
47 · median 44
Started
2012
with 1 other
Phase 1/2
4 of 38
none open now
Registered
4th of 38
by date
Lead sponsor
18 of 38
Novartis Pharmaceuticals

Among the 38 studies testing alpelisib in Breast Neoplasms, this one is the 16th largest by enrollment, is one of 2 that started in 2012, is one of 4 in phase 1/2, and was the 4th registered.

Breast Neoplasms

14,832 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

3 of the 38 studies testing alpelisib in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About alpelisib

Alpelisib: first FDA approval 2019 (PIQRAY), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing alpelisib in Breast Neoplasms, or all of them as a file.
02

Study summary

This was a multi-center, open-label, phase Ib/II study. The aim of the phase Ib part was to estimate the MTD(s) and/or identify the recommended phase II dose(s) (RP2Ds) for the combination of BYL719 and AMG 479 (ganitumab), followed by the phase II part to assess the clinical efficacy and to further assess the safety of the combination in selected patient populations. Patients were to be treated until progression of disease, unacceptable toxicity develops, or withdrawal of informed consent, whichever occurred first. All patients were to be followed up. At a minimum, patients must have completed the safety follow-up assessments 30 days after the last dose of the study treatment.

Read the detailed description

This was a multi-center, open-label, phase Ib/II study. The aim of the phase Ib part was to estimate the MTD(s) and/or identify the recommended phase II dose(s) (RP2Ds) for the combination of BYL719 and AMG 479 (ganitumab), followed by the phase II part to assess the clinical efficacy and to further assess the safety of the combination in selected patient populations. The dose escalation part of the study were to be guided by a Bayesian Logistic Regression Model (BLRM).

Once MTD/RP2D had been determined, patients were to be enrolled in two Phase II arms. Patients with PIK3CA mutated or amplified hormone receptor positive breast carcinoma were to be enrolled in Arm 1; patients with PIK3CA mutated or amplified ovarian carcinoma were to be enrolled in Arm 2. Patients were to be treated until progression of disease, unacceptable toxicity develops, or withdrawal of informed consent, whichever occurred first. All patients were to be followed up. At a minimum, patients must have completed the safety follow-up assessments 30 days after the last dose of the study treatment.

03

Conditions studied

  • PIK3CA Mutated Advanced Solid Tumors
  • PIK3CA Amplified Advanced Solid Tumors

Keywords

  • PIK3CA mutation
  • advanced solid tumor
  • breast cancer
  • ovarian cancer
  • cancers with a mass
  • bulky tumor
  • nodule
  • lump
  • advanced cancer
  • advanced solid malignancies
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion criteria:

  • Written .
  • Patients aged ≥ 18 years (male or female).
  • Patients with the following histologically/-confirmed advanced solid tumors with documented somatic PIK3CA mutations or amplifications in tumor tissue:
  • Hormone receptor positive breast carcinoma
  • Ovarian carcinoma
  • Other tumors upon agreement with sponsor
  • Adequate organ function
  • Negative serum pregnancy test

Key exclusion criteria:

  • Patients with known history of severe infusion reactions to monoclonal antibodies.
  • Patients with primary CNS tumor or CNS tumor involvement.
  • History of thromboembolic event requiring full-dose anti-coagulation therapy any time prior to enrollment.
  • cardiac disease.
  • History of another within last 2 years.
  • Pregnant or nursing (lactating) women.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    BYL719 + AMG 479

    For: Dose escalation phase/Phase II Expansion Phase. Cohorts of 3-6 patients were to be enrolled sequentially until an MTD or a recommended Phase II dose were defined. All patients were to receive the combination treatment. Sequential cohorts may receive different doses of the combination. In the Phase II expansion, all patients were to receive the same combination treatment.

    Drug: BYL719 · Drug: AMG 479

Interventions

  • DrugBYL719

    BYL719 is a small molecule inhibiting PI3-Kinase.

    Also known as: ALPELISIB

  • AMG 479 is a monoclonal antibody directed against IGF1-R.

    Also known as: ganitumab

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicities (DLTs) - Phase Ib

    Phase lb only

    Time frame: 28 days

  2. Percentage of Patients With Overall Response Rate (RECIST) Based on Investigator Radiology Assessment for HR Positive Breast and Ovarian Cancer - Phase II

    The antitumor activity of alpelisib in combination with ganitumab in patients with PIK3CA mutated or amplified hormone receptor positive (HR+) breast (arm 1) or ovarian (arm 2) cancer. Overall response rate is defined as the proportion of patients who have a best overall response of complete response or partial response assessed per RECIST 1.1.

    Time frame: Approximately 1 year (since initiation of Phase II, Dec 2013, till Primary CSR cut off 06Jan2015)

Secondary outcomes

  1. Number of Patients With Best Overall Response (RECIST) Based on Investigator Radiology Assessment - Phase Ib

    The anti-tumor activity of alpelisib and ganitumab in combination as per RECIST 1.1

    Time frame: Approximately 1 year (since FPFV 27Nov2012, till MTD declaration 26Nov2013)

  2. Percentage of Patients With Disease Control Rate (RECIST) Based on Investigator Radiology Assessment - Phase Ib

    The anti-tumor activity of alpelisib and ganitumab in combination as per RECIST 1.1

    Time frame: Approximately 1 year (since FPFV 27Nov2012, till MTD declaration 26Nov2013)

  3. Percentage of Patients With Disease Control Rate (RECIST) Based on Investigator Radiology Assessment for HR Positive Breast and Ovarian Cancer - Phase II

    the antitumor activity of alpelisib in combination with ganitumab in patients with PIK3CA mutated or amplified hormone receptor positive (HR+) breast (arm 1) or ovarian (arm 2) cancer. Phase II only, Cycle 1 Day 1 through Cycle 6 Day 28; assessed at baseline and every 8 weeks thereafter

    Time frame: Approximately 1 year (since initiation of Phase II, Dec 2013, till Primary CSR cut off 06Jan2015)

  4. Cmax of BYL - Phase Ib

    Serum concentration for BYL719 (alpelisib) 1 cycle - 28 days of treatment

    Time frame: Cycle 1 Day 1, Cycle 1 Day 15

  5. Area Under Curve (AUC) 0-24 Hour of BYL - Phase Ib

    Area under curve for BYL719 (alpelisib) 1 cycle - 28 days of treatment

    Time frame: Cycle 1 Day 1 (0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose), Cycle 1 Day 15 (0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose)

  6. Tmax and T Half of BYL - Phase Ib

    Tmax and half life of BYL719 (Alpelisib) 1 cycle - 28 days of treatment

    Time frame: Cycle 1 Day 1, Cycle 1 Day 15

  7. Cmax of AMG - Phase Ib

    Serum concentration for AMG 479 (ganitumab) 1 cycle - 28 days of treatment

    Time frame: Cycle 1 Day 15

  8. Area Under Curve (AUC) 0-336 Hour of AMG - Phase Ib

    Area under curve for AMG 479 (ganitumab) 1 cycle - 28 days of treatment

    Time frame: Cycle 1 Day 15 (0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose)

  9. Tmax and T Half of AMG - Phase Ib

    Tmax and half life of AMG 479 (ganitumab) 1 cycle - 28 days of treatment

    Time frame: Cycle 1 Day 15

07

Results

Posted Jun 28, 2018
Limitations and caveats
Due to the competitive landscape for anticancer therapies in ovarian and breast cancer and given the limited clinical activity observed with the study combination treatment, Novartis decided in 2014 to halt the recruitment in the trial.

Participant flow

Participant flow — Overall Study
MilestoneBYL 200mg + AMG 12mg/kgBYL 300mg + AMG 12mg/kgBYL 350mg + AMG 12mg/kgHR+BC - Phase IIOvarian - Phase IINon-HR+BC/Ovarian - Phase II
Started410101661
Completed000000
Not completed410101661
Withdrew: Adverse event134230
Withdrew: Death000101
Withdrew: Withdrawal by subject011000
Withdrew: Administrative problems010000
Withdrew: Disease progression3551330

Outcome measures

PrimaryDose Limiting Toxicities (DLTs) - Phase Ib

Phase lb only

Time frame:
28 days
Reported as:
Number · Participants
Dose Limiting Toxicities (DLTs) - Phase Ib
ParticipantsBYL 200mg + AMG 12mg/kgBYL 300mg + AMG 12mg/kgBYL 350mg + AMG 12mg/kg
Drug hypersensitivity001
Hyperglycemia001
Rash maculopapular010
Urticaria010
PrimaryPercentage of Patients With Overall Response Rate (RECIST) Based on Investigator Radiology Assessment for HR Positive Breast and Ovarian Cancer - Phase II

The antitumor activity of alpelisib in combination with ganitumab in patients with PIK3CA mutated or amplified hormone receptor positive (HR+) breast (arm 1) or ovarian (arm 2) cancer. Overall response rate is defined as the proportion of patients who have a best overall response of complete response or partial response assessed per RECIST 1.1.

Time frame:
Approximately 1 year (since initiation of Phase II, Dec 2013, till Primary CSR cut off 06Jan2015)
Reported as:
Number · Percentages of participants
Percentage of Patients With Overall Response Rate (RECIST) Based on Investigator Radiology Assessment for HR Positive Breast and Ovarian Cancer - Phase II
Percentages of participantsHR+BC - Phase IIOvarian - Phase IIAll Patients - Phase
Percentage of Patients With Overall Response Rate (RECIST) Based on Investigator Radiology Assessment for HR Positive Breast and Ovarian Cancer - Phase II12.5 (1.6 to 38.3)16.7 (0.4 to 64.1)13.0 (2.8 to 33.6)
SecondaryNumber of Patients With Best Overall Response (RECIST) Based on Investigator Radiology Assessment - Phase Ib

The anti-tumor activity of alpelisib and ganitumab in combination as per RECIST 1.1

Time frame:
Approximately 1 year (since FPFV 27Nov2012, till MTD declaration 26Nov2013)
Reported as:
Number · Participants
Number of Patients With Best Overall Response (RECIST) Based on Investigator Radiology Assessment - Phase Ib
ParticipantsBYL 200mg + AMG 12mg/kgBYL 300mg + AMG 12mg/kgBYL 350mg + AMG 12mg/kg
Complete response (CR)000
Partial response (PR)003
Stable disease (PD)132
Progressive disease (PD)333
Unknown042
SecondaryPercentage of Patients With Disease Control Rate (RECIST) Based on Investigator Radiology Assessment - Phase Ib

The anti-tumor activity of alpelisib and ganitumab in combination as per RECIST 1.1

Time frame:
Approximately 1 year (since FPFV 27Nov2012, till MTD declaration 26Nov2013)
Reported as:
Number · Percentages of participants
Percentage of Patients With Disease Control Rate (RECIST) Based on Investigator Radiology Assessment - Phase Ib
Percentages of participantsBYL 200mg + AMG 12mg/kgBYL 300mg + AMG 12mg/kgBYL 350mg + AMG 12mg/kg
Percentage of Patients With Disease Control Rate (RECIST) Based on Investigator Radiology Assessment - Phase Ib25.0 (0.6 to 80.6)9.1 (6.7 to 65.2)50.0 (18.7 to 81.3)
SecondaryPercentage of Patients With Disease Control Rate (RECIST) Based on Investigator Radiology Assessment for HR Positive Breast and Ovarian Cancer - Phase II

the antitumor activity of alpelisib in combination with ganitumab in patients with PIK3CA mutated or amplified hormone receptor positive (HR+) breast (arm 1) or ovarian (arm 2) cancer. Phase II only, Cycle 1 Day 1 through Cycle 6 Day 28; assessed at baseline and every 8 weeks thereafter

Time frame:
Approximately 1 year (since initiation of Phase II, Dec 2013, till Primary CSR cut off 06Jan2015)
Reported as:
Number · Percentages of participants
Percentage of Patients With Disease Control Rate (RECIST) Based on Investigator Radiology Assessment for HR Positive Breast and Ovarian Cancer - Phase II
Percentages of participantsHR+BC - Phase IIOvarian - Phase IIAll Patients - Phase II
Percentage of Patients With Disease Control Rate (RECIST) Based on Investigator Radiology Assessment for HR Positive Breast and Ovarian Cancer - Phase II43.8 (19.8 to 70.1)50.0 (11.8 to 88.2)47.8 (26.8 to 69.4)
SecondaryCmax of BYL - Phase Ib

Serum concentration for BYL719 (alpelisib) 1 cycle - 28 days of treatment

Time frame:
Cycle 1 Day 1, Cycle 1 Day 15
Reported as:
Mean · ng/mL
Cmax of BYL - Phase Ib
ng/mLBYL 200mg + AMG 12mg/kgBYL 300mg + AMG 12mg/kgBYL 350mg + AMG 12mg/kg
Cycle 1 Day 12070 ± 10402620 ± 12602640 ± 888
Cycle 1 day 153080 ± 17502880 ± 9102600 ± 1040
SecondaryArea Under Curve (AUC) 0-24 Hour of BYL - Phase Ib

Area under curve for BYL719 (alpelisib) 1 cycle - 28 days of treatment

Time frame:
Cycle 1 Day 1 (0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose), Cycle 1 Day 15 (0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose)
Reported as:
Mean · hr*ng/mL
Area Under Curve (AUC) 0-24 Hour of BYL - Phase Ib
hr*ng/mLBYL 200mg + AMG 12mg/kgBYL 300mg + AMG 12mg/kgBYL 350mg + AMG 12mg/kg
Cycle 1 Day 119900 ± 870023400 ± 1050025200 ± 9200
Cycle 1 day 1524000 ± 1070029700 ± 917025200 ± 9160
SecondaryTmax and T Half of BYL - Phase Ib

Tmax and half life of BYL719 (Alpelisib) 1 cycle - 28 days of treatment

Time frame:
Cycle 1 Day 1, Cycle 1 Day 15
Reported as:
Median · hr
Tmax and T Half of BYL - Phase Ib
hrBYL 200mg + AMG 12mg/kgBYL 300mg + AMG 12mg/kgBYL 350mg + AMG 12mg/kg
Tmax (Cycle 1 Day 1)2.78 (1.88 to 3.55)1.97 (0.63 to 3.00)2.36 (1.50 to 3.10)
Tmax (Cycle 1 Day 15)1.57 (0.83 to 1.83)3.01 (2.07 to 4.00)2.02 (2.00 to 3.08)
Thalf (Cycle 1 Day 1)7.78 (6.24 to 10.80)6.06 (5.26 to 13.70)6.86 (5.32 to 9.23)
Thalf (Cycle 1 Day15)6.89 (5.94 to 9.90)6.80 (5.82 to 8.81)6.83 (5.19 to 13.00)
SecondaryCmax of AMG - Phase Ib

Serum concentration for AMG 479 (ganitumab) 1 cycle - 28 days of treatment

Time frame:
Cycle 1 Day 15
Reported as:
Mean · ng/mL
Cmax of AMG - Phase Ib
ng/mLBYL 200mg + AMG 12mg/kgBYL 300mg + AMG 12mg/kgBYL 350mg + AMG 12mg/kg
Cmax of AMG - Phase Ib192 ± 24202 ± 43.3232 ± 59.3
SecondaryArea Under Curve (AUC) 0-336 Hour of AMG - Phase Ib

Area under curve for AMG 479 (ganitumab) 1 cycle - 28 days of treatment

Time frame:
Cycle 1 Day 15 (0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose)
Reported as:
Mean · hr*ng/mL
Area Under Curve (AUC) 0-336 Hour of AMG - Phase Ib
hr*ng/mLBYL 200mg + AMG 12mg/kgBYL 300mg + AMG 12mg/kgBYL 350mg + AMG 12mg/kg
Area Under Curve (AUC) 0-336 Hour of AMG - Phase Ib22900 ± 393022500 ± 704025200 ± 8000
SecondaryTmax and T Half of AMG - Phase Ib

Tmax and half life of AMG 479 (ganitumab) 1 cycle - 28 days of treatment

Time frame:
Cycle 1 Day 15
Reported as:
Median · hr
Tmax and T Half of AMG - Phase Ib
hrBYL 200mg + AMG 12mg/kgBYL 300mg + AMG 12mg/kgBYL 350mg + AMG 12mg/kg
Tmax21.20 (1.02 to 22.70)1.02 (1.00 to 23.10)1.07 (1.00 to 1.77)
Thalf132 (117 to 148)117 (109 to 161)180 (98 to 283)

Adverse events

Collected over Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BYL 200mg + AMG 12 mg/kg4/4 (100%)1/4 (25%)4/4 (100%)
BYL 300mg + AMG 12 mg/kg8/10 (80%)5/10 (50%)10/10 (100%)
BYL 350mg + AMG 12 mg/kg8/10 (80%)5/10 (50%)10/10 (100%)
HR + BC - Phase II13/16 (81.3%)9/16 (56.3%)16/16 (100%)
Ovarian - Phase II5/6 (83.3%)5/6 (83.3%)6/6 (100%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventBYL 200mg + AMG 12 mg/kgBYL 300mg + AMG 12 mg/kgBYL 350mg + AMG 12 mg/kgHR + BC - Phase IIOvarian - Phase II
HyperglycaemiaMetabolism and nutrition disorders0/40/101/102/163/6
Drug hypersensitivityImmune system disorders1/40/100/100/160/6
Abdominal painGastrointestinal disorders0/41/100/100/161/6
AstheniaGeneral disorders0/40/100/101/161/6
PyrexiaGeneral disorders0/40/100/100/161/6
Blood creatinine increasedInvestigations0/40/100/100/161/6
DehydrationMetabolism and nutrition disorders0/40/100/100/161/6
MyositisMusculoskeletal and connective tissue disorders0/40/100/100/161/6
Large intestinal obstructionGastrointestinal disorders0/41/100/100/160/6
Bile duct stenosisHepatobiliary disorders0/40/101/100/160/6
Most frequent other events
Showing 10 of 229
Most frequent other events
EventBYL 200mg + AMG 12 mg/kgBYL 300mg + AMG 12 mg/kgBYL 350mg + AMG 12 mg/kgHR + BC - Phase IIOvarian - Phase II
Decreased appetiteMetabolism and nutrition disorders1/45/106/108/166/6
NauseaGastrointestinal disorders0/49/105/107/163/6
Weight decreasedInvestigations2/45/109/106/162/6
HyperglycaemiaMetabolism and nutrition disorders1/47/109/109/164/6
FatigueGeneral disorders2/46/108/107/162/6
StomatitisGastrointestinal disorders3/43/105/106/163/6
Blood creatinine increasedInvestigations3/43/102/100/162/6
HeadacheNervous system disorders3/41/102/105/161/6
DiarrhoeaGastrointestinal disorders2/45/107/1010/163/6
VomitingGastrointestinal disorders0/46/104/104/163/6

Baseline characteristics

Full analysis set

Age, Continuous
Age, Continuous(years)BYL 200mg + AMG 12mg/kgBYL 300mg + AMG 12mg/kgBYL 350mg + AMG 12mg/kgHR+BC - Phase IIOvarian - Phase IINon-HR+BC/Ovarian - Phase IITotal
Mean50.5 ± 3.1157.5 ± 15.5563.7 ± 7.8351.3 ± 8.0459.7 ± 6.5356.0 ± 056.3 ± 10.54
Sex: Female, Male
Sex: Female, Male(Participants)BYL 200mg + AMG 12mg/kgBYL 300mg + AMG 12mg/kgBYL 350mg + AMG 12mg/kgHR+BC - Phase IIOvarian - Phase IINon-HR+BC/Ovarian - Phase IITotal
Female477156140
Male0331007
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)BYL 200mg + AMG 12mg/kgBYL 300mg + AMG 12mg/kgBYL 350mg + AMG 12mg/kgHR+BC - Phase IIOvarian - Phase IINon-HR+BC/Ovarian - Phase IITotal
Caucasian2810145140
Asian2202006
Native American0000101
08

Study locations

10 sites
  • Novartis Investigative Site
    Los Angeles, California 90095, United States
  • Novartis Investigative Site
    Boston, Massachusetts 02114, United States
  • Novartis Investigative Site
    New York, New York 10017, United States
  • Novartis Investigative Site
    Nashville, Tennessee 37203, United States
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Toronto, Ontario M5G 1Z6, Canada
  • Novartis Investigative Site
    Sevilla, Andalucia 41013, Spain
  • Novartis Investigative Site
    Barcelona, Catalunya 08035, Spain
  • Novartis Investigative Site
    Madrid, 28033, Spain
  • Novartis Investigative Site
    Madrid, 28041, Spain
09

References and documents

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2012 to primary completion in Dec 2014, 24 months.

Results were first posted in Jun 2018, 3 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2012
First posted
Oct 16, 2012
StartActual
Nov 27, 2012
Primary completionActual
Dec 26, 2014
CompletionActual
Jun 1, 2017
Results first posted
Jun 28, 2018
Last update
Sep 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01708161
Collaborators
NantCell, Inc.
Responsible party
Sponsor
First posted
Oct 16, 2012
Start date
Nov 27, 2012
Primary completion
Dec 26, 2014
Completion
Jun 1, 2017
Results posted
Jun 28, 2018
Last update
Sep 13, 2018

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Alpelisib · Ganitumab

Start the discussion